An interventional study of Home Based Fecal Calprotectin in Crohn Disease and Colitis, Ulcerative, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Diagnostic
Recently a smartphone application IBDoc® was developed to enable patients to measure faecal calprotectin at home in an easy way. In this HELP-AID trial we want to evaluate the value of these home based IBDoc® faecal calprotectin measurements in predicting short- and mid-term outcome to ADA induction therapy in patients with moderate-to-severe IBD.
Patients known with moderate-to-severe CD and ulcerative colitis starting ADA therapy will be asked to participate in this study. They will be asked to collect a stool sample at 3 different time points (week 0, 4 and 8). This faecal sample needs to be loaded on a test cassette with an extraction device. In a second step, the patient can turn his smartphone into an easy to use test cassette reader by taking a picture and using the CalApp® which is based on an immunochromatographic test. Finally, the CalApp® will transmit the test results securely to the health care professional.
In this study we want to evaluate the predictive value of absolute and relative faecal calprotectin values measured by IBDoc® on clinical, biological and endoscopic outcome at week 12. Furthermore, we want to evaluate the correlation between IBDoc® and classical ELISA measurements of faecal calprotectin, and the convenience of this system to the patient and the health care professional.
Adalimumab (Humira®), a fully human monoclonal antibody to TNF, has been given an important position in the treatment of patients with an inflammatory bowel disease (IBD). However, not all patients respond adequately to this relatively expensive and potentially toxic therapy. Adapting the standard treatment regimen to the individual needs of the patient may favor the short and long term outcome of this therapy.
Following daily clinical practice, patients will receive standard induction therapy with 160 mg adalimumab at week 0, followed by 80 mg adalimumab at week 2. Starting at week 4 patients will receive a maintenance therapy with 40 mg adalimumab every other week. If a patient shows an insufficient response, the dose can be increased to 40 mg adalimumab every week.
Defining predictors of response to ADA has become a major objective in scientific research. One of the predictors of response may be an early decrease in faecal calprotectin. Faecal calprotectin is a protein which presence in the stool of a patient correlates with endoscopic disease activity. A persistently elevated faecal calprotectin after start up with adalimumab treatment may suggest that this patient needs a higher dose.
Recently a smartphone application IBDoc® was developed to enable patients to measure faecal calprotectin at home in an easy way. In this HELP-AID trial we want to evaluate the value of these home based IBDoc® faecal calprotectin measurements in predicting short- and mid-term outcome to ADA induction therapy in patients with moderate-to-severe IBD.
Patients known with moderate-to-severe CD and ulcerative colitis starting ADA therapy will be asked to participate in this study. They will be asked to collect a stool sample at 3 different time points (week 0, 4 and 8). This faecal sample needs to be loaded on a test cassette with an extraction device. In a second step, the patient can turn his smartphone into an easy to use test cassette reader by taking a picture and using the CalApp® which is based on an immunochromatographic test. Finally, the CalApp® will transmit the test results securely to the health care professional.
In this study we want to evaluate the predictive value of absolute and relative faecal calprotectin values measured by IBDoc® on clinical, biological and endoscopic outcome at week 12. Furthermore, we want to evaluate the correlation between IBDoc® and classical ELISA measurements of faecal calprotectin, and the convenience of this system to the patient and the health care professional.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 140 is above the median of 66 across 1,188 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients. IBDoc® results will be forwarded to the patient and the health care professional.
Device: Home Based Fecal Calprotectin
Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
Also known as: IBDoc
In UC: Steroid-free mucosal healing (Mayo 0 or 1) at week 8 without prior need for ADA dose optimization, taking into account all kind of topical and systemic steroids.
The predictive value of an early faecal calprotectin amelioration (EFCA) measured by IBDoc between baseline and week 4, in predicting steroid-free mucosal healing (Mayo 0 or 1) at week 8 without prior need for ADA dose optimization, taking into account all kind of topical and systemic steroids. EFCA is defined as a decrease in faecal calprotectin measured by IBDoc between baseline and week 4 with at least 80% or a faecal calprotectin less than 50 μg/g at week 4.
Time frame: Week 8
In CD: Steroid-free clinical remission at week 12, defined as an Harvey-Bradshaw-Index <5 and a C-reactive protein <5 mg/L, without prior need for ADA dose optimization and taking into account all kind of topical and systemic steroids
The predictive value of EFCA measured by IBDoc® between baseline and week 4, in predicting steroid-free clinical remission at week 12 , defined as an Harvey-Bradshaw-Index \<5 and a C-reactive protein \<5 mg/L, without prior need for ADA dose optimization and taking into account all kind of topical and systemic steroids. EFCA is defined as a decrease in faecal calprotectin measured by IBDoc® between baseline and week 4 with at least 80% or a faecal calprotectin less than 50 μg/g at week 4.
Time frame: Week 12
In UC: The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 4
The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 4 in predicting: * steroid-free complete mucosal healing (Mayo 0) at week 8, and week 26, without prior need for ADA dose optimization; * steroid-free mucosal healing (Mayo 0 or 1) at week 26, without prior need for ADA dose optimization; * steroid-free clinical response (decrease from baseline in the total Mayo score ≥3 and ≥30% with a decrease in the rectal bleeding sub-score of ≥1 point or an absolute rectal bleeding sub-score 0 or 1) at week 8, week 12, and week 26, without prior need for ADA dose optimization; * steroid-free clinical remission (Mayo ≤2, no individual sub-score \>1) at week 8, week 12, and week 26, without prior need for ADA dose optimization; * ADA treatment optimization; * ADA treatment discontinuation;
Time frame: 4 weeks
In UC: The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 8
The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 8 in predicting: * steroid-free complete mucosal healing (Mayo 0) at week 26, without prior need for ADA dose optimization; * steroid-free mucosal healing (Mayo 0 or 1) at week 26, without prior need for ADA dose optimization; * steroid-free clinical response (decrease from baseline in the total Mayo score ≥3 and ≥30% with a decrease in the rectal bleeding sub-score of ≥1 point or an absolute rectal bleeding sub-score 0 or 1) at week 12, and week 26, without prior need for ADA dose optimization; * steroid-free clinical remission (Mayo ≤2, no individual sub-score \>1) at week 12, and week 26, without prior need for ADA dose optimization; * ADA treatment optimization; * ADA treatment discontinuation;
Time frame: 8 weeks
In CD: The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 4
The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 4 in predicting: * steroid-free clinical-remission at week 26, without prior need for ADA dose optimization; * steroid-free clinical response (HBI \<5 or drop in HBI with ≥3) at week 12, and week 26, without prior need for ADA dose optimization; * steroid-free biological remission (CRP \<5 mg/L) at week 12, and week 26, without prior need for ADA dose optimization; * steroid-free biological response (CRP \<5 mg/L or drop with ≥50%) at week 12, and week 26; * ADA treatment optimization; * ADA treatment discontinuation;
Time frame: 4 weeks
In CD: The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 8
The predictive value of an absolute and relative faecal calprotectin measured by IBDoc® between baseline and week 8 in predicting: * steroid-free clinical remission at week 26, without prior need for ADA dose optimization; * steroid-free clinical response (HBI \<5 or drop in HBI with ≥3) at week 12, and week 26, without prior need for ADA dose optimization; * steroid-free biological remission (CRP \<5 mg/L) at week 12, and week 26, without prior need for ADA dose optimization; * steroid-free biological response (CRP \<5 mg/L or drop with ≥50%) at week 12, and week 26, without prior need for ADA dose optimization; * ADA treatment optimization; * ADA treatment discontinuation;
Time frame: 8 weeks
In UC and CD: correlations with IBDoc® measurements of faecal calprotectin and ELISA measurements of faecal calprotectin, different components of the Mayo score, C reactive protein and serum albumin
The correlation between IBDoc® measurements of faecal calprotectin, ELISA measurements of faecal calprotectin, different components of the Mayo score, C reactive protein and serum albumin, at weeks 0, 4, 8, 12 and 26;
Time frame: 26 weeks
In UC and CD: The convenience of the IBDoc® system to the patient and the health care professional
The convenience of the IBDoc® system for patients, and health care professionals
Time frame: 26 weeks
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven